Biotech upstart gets $50M to test new virus-based therapies against solid tumors

The team at OncoMyx is trying to leverage one therapeutic to treat several forms of cancer, using the Myxoma virus. Wednesday, it announced the closing of a $50 million Series B financing to take it a step closer to that goal.